Azacitidine and Venetoclax as Induction Therapy With Venetoclax Maintenance in the Elderly With AML

Acute Myeloid Leukemia Clinical Trial

Official title:

Azacitidine and Venetoclax (ABT-199) as Induction Therapy With Venetoclax Maintenance in Previously Untreated Elderly Patients With Acute Myeloid Leukemia (AML)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03466294
• Other study ID #: 17-7821.cc
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: May 15, 2018
• Est. completion date: October 2025

Study information

• Verified date: June 2024
• Source: University of Colorado, Denver
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is being done to determine if treatment with azacitidine and venetoclax is effective treatment for elderly patients with acute myeloid leukemia (AML) who have not received previous treatment. Azacitidine and venetoclax will be given as induction treatment followed by venetoclax maintenance treatment for patients who respond to the induction treatment.

Description:

This is a phase 2 study for elderly patients who have not received previous treatment for acute myeloid leukemia (AML). Up to 42 patients will be enrolled. All patients will be treated with azacitidine and venetoclax until a minimal residual disease (MRD) negative response is achieved. Once patients achieve a MRD negative composite response, azacitidine will be discontinued and venetoclax dose will be decreased to "maintenance" dose.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 42
• Est. completion date: October 2025
• Est. primary completion date: December 15, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 60 Years and older

Eligibility

Inclusion Criteria:

1. Subject must have confirmation of non-APL AML by WHO criteria and be ineligible or unwilling to undergo treatment with a standard cytarabine and anthracycline induction regimen due to co-morbidities or other factors

2. Subject must have received no prior treatment for AML; hydroxyurea is not considered a treatment and is allowed

3. Subject must be = 60 years of age

4. Subject must have a projected life expectancy of at least 12 weeks

5. Subject must have an Eastern Cooperative Oncology Group (ECOG) Performance status of =2

6. Subject must have adequate renal function as demonstrated by a calculated creatinine clearance = 30 mL/min; determined via urine collection for 24-hour creatinine clearance or by the Cockcroft Gault formula

7. Subject must have adequate liver function as demonstrated by:

• aspartate aminotransferase (AST) = 3.0 × ULN*

• alanine aminotransferase (ALT) = 3.0 × ULN*

• bilirubin = 3.0 × ULN, unless due to Gilbert's syndrome*

• Unless considered due to leukemic organ involvement

8. Non-sterile male subjects must use contraceptive methods with partner(s) prior to beginning study drug administration and continuing up to 90 days after the last dose of study drug. Male subjects must agree to refrain from sperm donation from initial study drug administration until 90 days after the last dose of study drug.

9. Female subjects must be either:

• Postmenopausal; defined as Age > 55 years with no menses for 12 or more months without an alternative medical cause; OR

• Permanently surgically sterile (bilateral oophorectomy, bilateral salpingectomy or hysterectomy)

10. Subject must voluntarily sign and date an informed consent, approved by an Institutional Review Board (IRB), prior to the initiation of any screening or study-specific procedures.

Exclusion Criteria:

1. Subject has received treatment with a hypomethylating agent and/or other chemotherapeutic agent either conventional or experimental for myelodysplastic syndrome (MDS) or AML

2. Subject has acute promyelocytic leukemia

3. Subject has known active CNS involvement from AML

4. Subject is known to be positive for HIV. HIV testing is not required

5. Subject is known to be positive for hepatitis B or C infection with the exception of those with an undetectable viral load. Hepatitis B or C testing is not required and subjects with serologic evidence of prior vaccination to HBV (i.e., HBs Ag, anti-HBs+ and anti-HBc-) may participate

6. Subject has received anticancer therapies including chemotherapy, radiotherapy or other investigational therapy, including targeted small molecule agents within 5 half-lives prior to first dose of study drug

7. Subject has received biologic agents (e.g. monoclonal antibodies) for anti-neoplastic intent within 30 days prior to first dose of study drug

8. Subject has received the following within 7 days prior to the first dose of the study drug:

• Steroid therapy for anti-neoplastic intent;

• Strong and Moderate CYP3A inhibitors (see Appendix A for examples)

• Strong and Moderate CYP3A inducers (see Appendix A for examples)

9. Subject has consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges) or Star fruit within 3 days prior to the initiation of study treatment

10. Subject has any history of clinically significant condition(s) that in the opinion of the investigator would adversely affect his/her participating in this study including, but not limited to:

• New York Heart Association heart failure > class 2

• Renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, hepatic, cardiovascular disease, or bleeding disorder independent of leukemia

11. Subject has a malabsorption syndrome or other condition that precludes enteral route of administration

12. Subject exhibits evidence of uncontrolled systemic infection requiring therapy (viral, bacterial or fungal)

13. Subject has a history of other malignancies prior to study entry, with the exception of:

• Adequately treated in situ carcinoma of the breast or cervix uteri

• Basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin

• Prostate cancer with no plans for therapy of any kind

• Previous malignancy confined and surgically resected (or treated with other modalities) with curative intent

14. Subject has a white blood cell count > 25 × 109/L. Note: hydroxyurea is permitted to meet this criteria

15. Any subject who is a candidate for intensive induction therapy and agrees to receive this therapy

Related Conditions & MeSH terms

• Acute Myeloid Leukemia
• Leukemia
• Leukemia, Myeloid
• Leukemia, Myeloid, Acute

Intervention

Drug:
• Azacitidine and Venetoclax
Azacitidine will be given at dose of 75mg/m2 in Cycle 1 days 1-7; repeat in cycle 2 and 3 if no response. Starting on day 2 of cycle 1, venetoclax will be administered orally with doses increased to a target dose of 600 mg (administer 100 mg on day 2, 200 mg on day 3, 400 mg on day 4 and 600 mg on day 5), then 600 mg daily.

Locations

Country	Name	City	State
United States	University of Colorado Denver	Aurora	Colorado

Sponsors (1)

Lead Sponsor	Collaborator
University of Colorado, Denver

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Duration of response to azacitidine and venetoclax treatment	Determine how long responses last in patients treated with azacitidine and venetoclax followed by venetoclax maintenance treatment	From the first day a response is documented to the first day of disease progression
Secondary	Frequency of Minimal Residual Disease (MRD) negative composite responses within the "induction phase" of azacitidine and venetoclax	The number of patients who achieve an MRD negative composite response	From Day 28, the first day a response is documented to end of cycle bone marrow biopsies, through 5 years
Secondary	The time needed to achieve an MRD negative composite response	The median number of days that have elapsed leading to an MRD negative composite response	From first dose of treatment to first day response is documented by bone marrow biopsy
Secondary	The one-year overall survival (OS) of older, newly diagnosed AML patients treated with "induction phase" of azacitidine with venetoclax followed by a maintenance Phase of venetoclax alone.	The number of patients who survive to one year after date of study enrollment	From date of study enrollment to one year after enrollment
Secondary	Hematologic Toxicity as defined by the 2017 ELN AML Recommendations	Hematologic toxicities will be measured by incidence of febrile neutropenia, = grade 2 bleeding complications and number of transfusions received	From the day venetoclax with azacitidine is administered to the end of maintenance venetoclax alone, up to one year